Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Engineered cord blood cells take on resistant lymphoma

NCT ID NCT06707259

First seen Nov 20, 2025 · Last updated May 23, 2026 · Updated 36 times

Summary

This early-phase study tests a new treatment made from cord blood cells that are engineered to find and attack cancer cells in people with B-cell non-Hodgkin lymphoma that has not responded to standard therapy. About 24 adults aged 18 to 75 will receive these special immune cells to see if they are safe and can shrink tumors. The goal is to find the right dose and measure how well the treatment controls the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL NON HODGKIN LYMPHOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • the Second Affiliated Hospital, College of Medicine, Zhejiang University

    RECRUITING

    Hangzhou, Zhejiang, 310009, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.